Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Free Report) – Equities researchers at HC Wainwright issued their Q1 2027 earnings estimates for shares of Sensei Biotherapeutics in a research report issued on Monday, June 22nd. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of ($0.78) for the quarter. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q2 2027 earnings at ($0.87) EPS, Q3 2027 earnings at ($0.96) EPS, Q4 2027 earnings at ($1.06) EPS, FY2028 earnings at ($3.19) EPS, FY2029 earnings at ($3.16) EPS and FY2030 earnings at ($3.07) EPS.
FTH has been the topic of several other reports. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Weiss Ratings assumed coverage on Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $60.00.
Sensei Biotherapeutics Stock Performance
Shares of NASDAQ FTH opened at $23.19 on Tuesday. Sensei Biotherapeutics has a 1 year low of $6.32 and a 1 year high of $36.76.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.
Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.
Further Reading
- Five stocks we like better than Sensei Biotherapeutics
- SpaceX Valuation Loses Altitude as AI Risks Mount
- Copa Holdings May Be the Airline Stock Built to Break Out
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
